Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.67 |
| ▸ | PADI1 | Q9ULC6 | 5/20 | 0.62 |
| ▸ | PADI4 | Q9UM07 | 5/20 | 0.62 |
| ▸ | PADI2 | Q9Y2J8 | 4/20 | 0.62 |
| ▸ | PDE4A | P27815 | 3/20 | 0.62 |
| ▸ | PADI3 | Q9ULW8 | 3/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.62 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28281357 | 1.00 | HPGDS (0.67) | HPGDSPADI1PADI4PADI2PDE4A | |
| SCHEMBL13697775 | 0.92 | HPGDS (0.71) | HPGDSPADI1PADI4PADI2PDE4A | |
| SCHEMBL607886 | 0.89 | ITGB3 (0.60) | HPGDSPADI1PADI4PADI2PDE4A | |
| SCHEMBL607885 | 0.89 | ITGB3 (0.60) | HPGDSPADI1PADI4PADI2PDE4A | |
| SCHEMBL1226872 | 0.87 | HPGDS (0.65) | HPGDSPADI1PADI4PADI2PDE4A | |
| SCHEMBL7293567 | 0.87 | HPGDS (0.52) | HPGDSPADI1PADI4PADI2PDE4A | |
| SCHEMBL7411072 | 0.85 | CTSB (0.57) | HPGDSCTSBITGB3ITGA2BGRIN1 | |
| SCHEMBL27544597 | 0.85 | CTSB (0.57) | HPGDSCTSBITGB3ITGA2BGRIN1 | |
| SCHEMBL4181143 | 0.85 | PADI1 (0.62) | HPGDSPADI1PADI4PADI2PDE4A | |
| SCHEMBL1980652 | 0.84 | ITGB3 (0.57) | HPGDSPADI1PADI4PADI2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1038103-A | The glutaramide diuretic agents of cycloalkyl substituted and its preparation method | PFIZER (US) | 1989-12-20 | — | — | CN | claimed |
| US-8580534-B2 | Method for incorporation of two oxygen atoms into digested peptides using peptidases | THE UNIVERSITY OF NORTH DAKOTA (US) | 2013-11-12 | — | — | US | disclosed |
| EP-1551864-B1 | Substrates for detection of TAFI(a) | DSM IP ASSETS BV (NL) | 2011-11-09 | — | — | EP | disclosed |
| US-7718406-B2 | Substrates for TAFI (A) | DSM IP ASSETS B.V. (NL) | 2010-05-18 | — | — | US | disclosed |
| US-20080032322-A1 | Method for incorporation of two oxygen atoms into digested peptides using peptidases | UNIVERSITY OF NORTH DAKOTA (US) | 2008-02-07 | — | — | US | disclosed |
| US-20060068457-A1 | Substrates for tafi (a) | PENTAPHARM AG (CH) | 2006-03-30 | — | — | US | disclosed |
| EP-1551864-A1 | SUBSTRATE FOR TAFI (A) | Pentapharm AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031216-A1 | SUBSTRATE FOR TAFI (A) | PENTAPHARM AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| EP-0367302-A2 | Process for semi-synthesis of human insulin, water-soluble cross-linked Achromobacter protease I for use therein and a process for preparing the same | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
| EP-0092829-A2 | Process for semi-synthesis of human insulin and alkaline protease for use therein | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060068457-A1 | Substrates for tafi (a) | TFPI, TFPI2, FGB | HPGDS 1703/4885PADI1 162/4885PADI4 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.